NCT05121350View on ClinicalTrials.gov

A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma

PHASE3UnknownINTERVENTIONAL
Enrollment

256

Participants

Timeline

Start Date

March 31, 2022

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2024

Conditions
Soft Tissue Sarcoma
Interventions
DRUG

Anlotinib hydrochloride capsule

Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor.

DRUG

Epirubicin

Epirubicin can inhibit the synthesis of DNA and RNA.

DRUG

Arotinib hydrochloride capsule placebo

Placebo of Anlotinib hydrochloride capsule

Trial Locations (3)

100032

RECRUITING

Beijing Jishuitan Hospital, Beijing

100044

RECRUITING

Peking University People's Hospital, Beijing

200032

RECRUITING

Fudan University Zhongshan Hospital, Shanghai

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY